Topic Highlight
Copyright ©The Author(s) 2015.
World J Gastroenterol. Nov 7, 2015; 21(41): 11767-11776
Published online Nov 7, 2015. doi: 10.3748/wjg.v21.i41.11767
Table 1 Hepatic metastasectomy: Large retrospective studies
Ref.Patients, nMedian overall survival (mo)5-yr survival10-yr survival20-yr survival
Rees et al[19], 200892936%23%
Choti et al[17], 20022264640%26%
Fong et al[22], 199910014237%22%
Nordlinger et al[18], 1996156828%
Scheele et al[20], 19954344033%20%17%
Table 2 Retrospective studies of patients with unresected liver metastases
Ref.Patients without extrahepatic metastases, nThe extent of liver involvementMedian overall survival (mo)Treatments
Yamamura et al[41], 1997 (n = 73)67Metastases in one lobe13Chemotherapy (chemotherapy did not significantly affect survival in multivariate analysis)
Less than four metastases in both lobes12
More than five metastases in both lobes6
Stangl et al[39], 1994189 ≤ 25%11.1No treatment
> 25%6.3
Chang et al[38], 1989 (n = 67)4915.1Floxuridine (hepatic arterial or intravenously)
< 25%23.8
25%-75%14.8
> 75%7.3
Arnaud et al[40], 1984 (n = 56)(not specified)One lobe17NA
Both lobes8.23
Johnson et al[42], 198151Solitary liver metastasis (n = 12)18NA
Multiple metastases in one lobe (n = 6)7
Multiple metastases in both lobes (n = 33)8
Table 3 Retrospective studies including ≥ 100 patients with resectable lung metastases from colorectal cancer
Ref.Yearnmedian survival (mo)5-yr survival rate (%)
Borasio et al[66]201113736.255
Hwang et al[67]20101253748
Riquet et al[68]20101274541
Watanabe et al[69]2009113NA68
Welter et al[70]200716947.239
Yedibela et al[71]20061534337
Inoue et al[72]20041284945
Kanemitsu et al[73]20043133838
Pfannschmidt et al[74]20031674032
Saito et al[75]2002165NA40
Zink et al[76]20011104132